Belantamab Mafodotin (GSK2857916)
CAS: 2050232-20-5
Description:
Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) designed to treat multiple myeloma. It combines an anti-B-cell maturation antigen (BCMA) monoclonal antibody with the cytotoxic agent monomethyl auristatin F (MMAF). The antibody targets BCMA, a protein overexpressed on malignant plasma cells, and delivers MMAF directly to the tumor. MMAF disrupts microtubules, causing cancer cell death. Doctors use belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who have received prior therapies.
Key Features:
- BCMA Targeting: The antibody binds to BCMA on malignant plasma cells, enabling precise drug delivery.
- Cytotoxic Agent (MMAF): MMAF disrupts microtubules, leading to cancer cell death.
- Linker Technology: The stable linker ensures targeted delivery of MMAF to cancer cells.
Applications:
- Cancer Treatment: Targets and kills BCMA-positive multiple myeloma cells.
- Targeted Therapy: Delivers MMAF directly to cancer cells, sparing healthy tissue.
- Monoclonal Antibody Therapy: Provides an effective treatment for relapsed or refractory multiple myeloma, offering a more precise chemotherapy approach.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.